Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label Extension Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis

NCT05626751 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT05626751
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05626751 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label Extension Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Terminated
Start date
November 4, 2022
Completion date
February 24, 2025
Enrollment
174 (actual)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse cutaneous systemic sclerosis, sclerosis, systemic